The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $18.88

Today's change0.00 0.00%
Updated April 1 4:00 PM EDT. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $18.88

Today's change0.00 0.00%
Updated April 1 4:00 PM EDT. Delayed by at least 15 minutes.

Meridian Bioscience Inc down slightly

Meridian Bioscience Inc closed down just (U.S.)$0.00 Wednesday to (U.S.)$18.88. Shares have lost 1.72% over the last five days, but have gained 14.70% over the last year to date. This security has underperformed the S&P 500 by 22.95% during the last year.

Key company metrics

  • Open(U.S.) $18.96
  • Previous close(U.S.) $18.88
  • High(U.S.) $19.09
  • Low(U.S.) $18.75
  • Bid / Ask-- / --
  • YTD % change+14.70%
  • Volume336,700
  • Average volume (10-day)307,714
  • Average volume (1-month)279,221
  • Average volume (3-month)308,303
  • 52-week range(U.S.) $15.56 to (U.S.) $23.13
  • Beta1.42
  • Trailing P/E22.54×
  • P/E 1 year forward21.89×
  • Forward PEG2.05×
  • Indicated annual dividend(U.S.) $0.80
  • Dividend yield4.24%
  • Trailing EPS(U.S.) $0.84
Updated April 1 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.34%

Based on its net profit margin of 18.34%, Meridian Bioscience Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.27%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue48474750
Total other revenue--------
Total revenue48474750
Gross profit29282932
Total cost of revenue19181819
Total operating expense35353434
Selling / general / administrative13131313
Research & development3333
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--0----
Other operating expenses, total--------
Operating income13121316
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax12121316
Income after tax88910
Income tax, total4445
Net income88910
Total adjustments to net income--------
Net income before extra. items88910
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items88910
Inc. avail. to common incl. extra. items88910
Diluted net income88910
Dilution adjustment----0--
Diluted weighted average shares42424242
Diluted EPS excluding extraordinary itemsvalue per share0.190.200.210.24
Dividends per sharevalue per share0.200.200.200.20
Diluted normalized EPSvalue per share0.190.200.210.24